What question did this study set out to answer?

To assess whether continuation of mycophenolate mofetil after rituximab improves treatment outcomes in pemphigus.

January 22, 2026

Treatment with mycophenolate mofetil as an adjuvant therapy post-rituximab does not improve treatment outcomes in pemphigus

Puntos clave

To assess whether continuation of mycophenolate mofetil after rituximab improves treatment outcomes in pemphigus.
Evaluated patients receiving rituximab and mycophenolate mofetil post-treatment
Compared clinical outcomes of patients on mycophenolate mofetil with prednisolone to those on prednisolone alone
Analyzed lymphocyte counts to assess T cell levels
No significant improvement in treatment responses was noted with mycophenolate mofetil
Adjuvant mycophenolate mofetil resulted in CD8 T cell lymphopaenia
Increased risk of infection was suggested in patients receiving mycophenolate mofetil

Resumen

Rituximab is an effective treatment for pemphigus but it is not known whether continuation of mycophenolate mofetil (MMF) after treatment improves clinical outcomes. This study demonstrates that continuation of MMF with prednisolone is not associated with improved or prolonged treatment responses compared to prednisolone alone. Adjuvant treatment with MMF was, however, associated with a CD8 T cell lymphopaenia suggestive of an increased risk of infection.

Me gusta

Guardar

Cite This Study

Naidu et al. (Thu,) studied this question.

synapsesocial.com/papers/6971be10642b1836717e2bb4 https://doi.org/https://doi.org/10.1093/ced/llag017

Me gusta

Guardar